Summary by Moomoo AI
SINDA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT MR. CHI-HO WILL RETIRE AS CHIEF FINANCIAL OFFICER FROM FEBRUARY 5, 2024, BUT WILL REMAIN AN EXECUTIVE DIRECTOR AND PARTICIPATE IN THE BOARD'S STRATEGIC AND BUSINESS DECISIONS. SINCE JOINING THE COMPANY IN 2017, MR. CHI-HO HAS MADE SIGNIFICANT CONTRIBUTIONS TO THE COMPANY'S STRATEGY, CORPORATE GOVERNANCE, FINANCIAL MANAGEMENT AND BUSINESS DEVELOPMENT, AND SUCCESSFULLY LED THE COMPANY'S LISTING AND SUBSEQUENT FINANCING ACTIVITIES ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE LIMITED. At the same time, the Board of Directors announced that Ms. Fei will be appointed as the new Chief Financial Officer. Ms. Fei has more than 20 years of financial management and strategic investment experience and has held senior positions at such companies as Kam Hin Reproductive Medical Group Limited and Sansheng Pharmaceuticals. The Board of Directors is grateful for Mr. Chi-ho's contributions and welcomes Ms. Fei's participation, and looks forward to helping the company achieve its mission and vision.